Cognitive Impairment in Multiple Sclerosis

Overview

Journal J Neurol

Specialty Neurology

Date 2007 May 16

PMID 17503127

Citations 19

Authors

Alexander Winkelmann

Claudia Engel

Annett Apel

Uwe K Zettl

Affiliations

Soon will be listed here.

Abstract

Cognitive dysfunctions are frequent symptoms of multiple sclerosis (MS) and occur in up to 65% of patients. Especially memory, attention, executive and visual constructive functions are impaired. These problems strongly affect patients' ability to work, social relationships, and quality of life. Symptoms of physical disabilities can arise independently. Cognitive dysfunctions are clear indicators of MS progression, because they represent highly complex functions that depend on the integrity of the neuronal networks. Once manifested after a relapse, they remain stable . Given a differentiating diagnosis, it is possible to treat these dysfunctions by cognitive training and with pharmaceutical drugs, for example by immunomodulating drugs. However, treatment options are limited at present. This report provides a detailed description of cognitive functions and performance in MS patients, their comorbidities such as fatigue and depression and therapeutic options.

Citing Articles

Protocol for the MS-CEBA study: an observational, prospective cohort study identifying Cognitive, Energetic, Behavioural and Affective (CEBA) profiles in Multiple Sclerosis to guide neuropsychological treatment choice.

Reinhardt A, Rakers S, Heersema D, Beenakker E, Meilof J, Timmerman M BMC Neurol. 2024; 24(1):224.

PMID: 38943063 PMC: 11212448. DOI: 10.1186/s12883-024-03737-6.

Investigating the Impact of Polypharmacy and Anticholinergic Medication Burden on Objective Cognitive Performance in Adults With Multiple Sclerosis.

Huebner J, Robichaud J, Cozart J, Burkhardt C, Lynch S, Bruce J Int J MS Care. 2024; 26(2):81-88.

PMID: 38482514 PMC: 10930810. DOI: 10.7224/1537-2073.2023-014.

Is There Reduced Hemodynamic Brain Activation in Multiple Sclerosis Even with Undisturbed Cognition?.

Wagner B, Harig C, Walter B, Sommer J, Sammer G, Berghoff M Int J Mol Sci. 2023; 24(1).

PMID: 36613551 PMC: 9820283. DOI: 10.3390/ijms24010112.

Clinical application of transcranial magnetic stimulation in multiple sclerosis.

Zhou X, Li K, Chen S, Zhou W, Li J, Huang Q Front Immunol. 2022; 13:902658.

PMID: 36131925 PMC: 9483183. DOI: 10.3389/fimmu.2022.902658.

Effect of Donepezil on Cognitive Impairment, Quality of Life, and Depression in Multiple Sclerosis Patients: A Randomized Clinical Trial.

Shahpouri M, Barekatain M, Tavakoli M, Badihian S, Shaygannejad V Int J Prev Med. 2020; 11:69.

PMID: 32742613 PMC: 7373083. DOI: 10.4103/ijpvm.IJPVM_154_19.

References

Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin L, Tommasi M . A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001; 70(6):773-80. PMC: 1737379. DOI: 10.1136/jnnp.70.6.773. View

Rovaris M, Filippi M, Falautano M, Minicucci L, Rocca M, Martinelli V . Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology. 1998; 50(6):1601-8. DOI: 10.1212/wnl.50.6.1601. View

Flachenecker P, Kumpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P . Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler. 2002; 8(6):523-6. DOI: 10.1191/1352458502ms839oa. View

Henze T, Rieckmann P, Toyka K . Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006; 56(2):78-105. DOI: 10.1159/000095699. View

Pelosi L, Geesken J, Holly M, Hayward M, Blumhardt L . Working memory impairment in early multiple sclerosis. Evidence from an event-related potential study of patients with clinically isolated myelopathy. Brain. 1997; 120 ( Pt 11):2039-58. DOI: 10.1093/brain/120.11.2039. View

Feinstein A . The neuropsychiatry of multiple sclerosis. Can J Psychiatry. 2004; 49(3):157-63. DOI: 10.1177/070674370404900302. View

Barak Y, Gabbay U, Glad R, Sarova-Pinhas I, Achiron A . Neuropsychiatric assessment as a secondary outcome measure in a multiple sclerosis intravenous immunoglobulin L(IMg) trial. Int J Psychiatry Clin Pract. 2014; 3(1):31-4. DOI: 10.3109/13651509909024756. View

Arnett P, Higginson C, Voss W, Wright B, Bender W, Wurst J . Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning. Neuropsychology. 1999; 13(3):434-46. DOI: 10.1037//0894-4105.13.3.434. View

Zephir H, De Seze J, Dujardin K, Dubois G, Cabaret M, Bouillaguet S . One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. Mult Scler. 2005; 11(3):360-3. DOI: 10.1191/1352458505ms1172sr. View

10.

Fraser C, Stark S . Cognitive symptoms and correlates of physical disability in individuals with multiple sclerosis. J Neurosci Nurs. 2004; 35(6):314-20. DOI: 10.1097/01376517-200312000-00005. View

11.

Bjartmar C, Trapp B . Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol. 2001; 14(3):271-8. DOI: 10.1097/00019052-200106000-00003. View

12.

Herholz K . Cognitive dysfunction and emotional-behavioural changes in MS: the potential of positron emission tomography. J Neurol Sci. 2006; 245(1-2):9-13. DOI: 10.1016/j.jns.2005.09.012. View

13.

Sperling R, Guttmann C, Hohol M, Warfield S, Jakab M, Parente M . Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study. Arch Neurol. 2001; 58(1):115-21. DOI: 10.1001/archneur.58.1.115. View

14.

Litvan I, Grafman J, Vendrell P, Martinez J, Junque C, Vendrell J . Multiple memory deficits in patients with multiple sclerosis. Exploring the working memory system. Arch Neurol. 1988; 45(6):607-10. DOI: 10.1001/archneur.1988.00520300025012. View

15.

Benedict R, Cox D, Thompson L, Foley F, Weinstock-Guttman B, Munschauer F . Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler. 2004; 10(6):675-8. DOI: 10.1191/1352458504ms1098oa. View

16.

Krupp L, Alvarez L, Larocca N, SCHEINBERG L . Fatigue in multiple sclerosis. Arch Neurol. 1988; 45(4):435-7. DOI: 10.1001/archneur.1988.00520280085020. View

17.

Weinstein A, Schwid S, Schiffer R, McDermott M, Giang D, Goodman A . Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol. 1999; 56(3):319-24. DOI: 10.1001/archneur.56.3.319. View

18.

Grant I, McDonald W, Trimble M, Smith E, REED R . Deficient learning and memory in early and middle phases of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1984; 47(3):250-5. PMC: 1027722. DOI: 10.1136/jnnp.47.3.250. View

19.

Christodoulou C, Melville P, Scherl W, MacAllister W, Elkins L, Krupp L . Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci. 2006; 245(1-2):127-36. DOI: 10.1016/j.jns.2005.08.021. View

20.

Dujardin , Donze , Hautecoeur . Attention impairment in recently diagnosed multiple sclerosis. Eur J Neurol. 1999; 5(1):61-66. DOI: 10.1046/j.1468-1331.1998.510061.x. View